Summary
Introduction
Fibronectin, a high-molecular-weight glycoprotein, also known as cold insoluble globulin, is widely distributed in the tissues, plasma and tissue fluids 11-31. It is a product of mesenchymal cells and there has recently been considerable interest in its role in both normal and pathological states 141. Its ability to bind to fibrin(ogen) and to collagen suggests that it may have a major role in the tissue response to an inflammatory stimulus. Rheumatoid arthritis is characterized by fibrin deposition, fibrosis and pannus formation, and we have recently shown, in an immunohistochemical study [51, that fibronectin is present in the synovium in increased amounts in rheumatoid arthritis and is related to fibrin deposition and fibrosis. We now report a detailed investigation of plasma and synovial fluid fibronectin levels in rheumatoid arthritis and an evaluation of the significance of these levels in relation to clinical, immunochemical and haematological changes.
Patients and methods

Subjects studied
Eighty-eight consecutive patients with definite or classical rheumatoid arthritis 161 attending a rheumatology clinic gave plasma and serum specimens. Synovial fluid specimens were collected from 62 additional patients requiring diagnostic or therapeutic joint aspirations. The majority of these had rheumatoid arthritis by the same criteria, but some had oestoarthritis, seronegative arthritis, as defined by Wright & Moll 171, or psoriatic arthritis. Control plasma and serum samples were obtained from 60 healthy donor subjects attending a blood transfusion centre. All subjects in the study gave informed consent for specimens to be collected. Details of the patients and controls are given in Table 1 . 
Characteristics of arthritic patients
The duration of early morning stiffness and the Ritchie index [81 were recorded. The haemoglobin concentration, leucocyte count, platelet count and erythrocyte sedimentation rate (Westergen) were measured. Tests for IgM rheumatoid factor (sheep cell agglutination titre) and antinuclear factor (by indirect immunofluorescence) were performed.
CoUection of specimens
Plasma and synovial fluid were collected aseptically into sterile tubes and anticoagulated with 1% (w/v) disodium ethylenediamine-tetraacetic acid (EDTA) and then centrifuged (10 min at 1500 g) to remove cellular and other material. Serum was similarly collected. Specimens were collected in the morning (10.00-12.00 hours). Samples were immediately frozen at -8OOC until analysed. Additional synovial fluid specimens were analysed (see below) without centrifugation or storage. For immunochemical analyses, synovial fluid specimens were incubated at 24OC for 15 min with 5% (w/v) hyaluronidase at 1500 units/ml (ovine: Fisons Ltd) after thawing. 1121 . The fibronectin was further purified by the removal of minor contaminating plasma proteins by chromatography on a Sephacryl S300 (Pharmacia Ltd) column and elution with a buffer containing Tris (0.05 mol/l)/NaCl (0.1 mol/l) adjusted with HCl to pH 7.6. The purity of the final product was assessed in several ways: on sodium dodecyl sulphate (SDS)/polyacrylamidegel electrophoresis it gave a single band (mol. wt. 220 OOO) when run on 5% (w/v) gels in reducing conditions: in two-dimensional immunoelectrophoresis performed as described by Clarke & Freeman [ 131 it gave a single protein peak with antiserum to whole human serum (Wellcome).
Tests on synovialfluid
The purified fibronectin was homogenized in Freund's complete adjuvant and injected subcutaneously and intramuscularly into rabbits. Subsequent injections were made intracutaneously without adjuvant in a dosage schedule described previously by Soothill 1141. When necessary, antiserum produced by this method was rendered monospecific by absorption of the antisera with the fibronectin-free supernatant from the first step of the isolation procedure as absorbant. The final antisera obtained were monospecific when tested with serum or plasma on double immunodiffusion and with both one-dimensional immunoelectrophoresis performed in 1% (w/v) agar (containing barbiturate buffer at ionic strength 0.05 at pH 8.6) using a modification of the technique of Scheidegger [ 151 and two-dimensional imrnunoelectrophoresis. The antisera gave single precipitin arcs producing a 'reaction of identity' with two reference antisera: (a) a commercial antiserum obtained from Hoechst Ltd, and (b) an antiserum to plasma fibronectin kindly provided by Dr J. Bums, Department of Pathology, University of Oxford.
Estimation offibronectin levels
The concentration of fibronectin in plasma and synovial fluid was measured by both 'rocket' immunoelectrophoresis [ 
Other immunochemical investigations
Serum and synovial fluid were examined for levels of immuno'globuliis (Ig) G, A and M by single radial immunodiffusion 1171. In each case monospecific antiserum and highly purified protein standards (from Department of Immunology, University of Birmingham) or pooled serum standards were used. C-reactive protein and haptoglobin in these specimens were estimated as described previously 1201.
ImmunoJuorescence studies
Air-dried synovial fluid smears were fixed in cold acetone (4OC) for 60 s and then examined by the indirect immunofluorescence technique as described by Nairn 1211. They were treated with the rabbit anti-(human fibronectin) antiserum and then with fluorescein-labelled sheep anti-(rabbit immunoglobulin) antiserum. Control smears were examined after treatment with both nonimmunized rabbit serum followed by fluoresceinlabelled sheep anti-(rabbit immunoglobulin) and after treatment with the latter antiserum alone. Smears were subsequently stained with phosphotungstic acid/haematoxylin for light microscopy. Immunofluorescence was performed with a Zeiss S 14 indirect-light fluorescence microscope.
?=rrults
Plasma and synovialfluidjibronectin (Fig. 1 ) Plasma fibronectin levels were similar in patients with rheumatoid arthritis (mean 0.35 g/l, SD 0.11; n = 88) and control subjects (mean 0.33 g/l, SD 0.1 1; n = 60), as shown in negative arthritis (mean 0.51 g/l, SD 0.19; n = 7) and psoriatic arthritis (mean 0-60 g/l, SD 0.11; n = 6).
A comparison of plasma and synovial fluid fibronectin levels in specimens taken concurrently in patients with rheumatoid arthritis confirmed that synovial fluid levels were higher than plasma levels in the group as a whole ( P < 0.01; Wilcoxon rank-sum test). But individual results (Fig. 2) showed that this pattern was not of uniform occurrence in individual patients, and there was no correlation between plasma and synovial fluid fibronectin levels.
Relation of plasma Jibronectin to disease activity in rheumatoid arthritis
Plasma fibronectin levels were unrelated to most indices of disease activity in rheumatoid arthritis (Table 2) nor to drug therapy, and there was no evidence that fibronectin behaved like known acute-phase reactants (C-reactive protein or haptoglobin). Plasma fibronectin levels were also unrelated to the presence or absence of rheumatoid factor, IgG antinuclear factor or to the respective titres of these autoantibodies. 
-
Relation between jbronectin levels and other changes in synovialjluid
The level of fibronectin measured in joint fluid was unrelated to polymorphonuclear leucocyte, lymphocyte or synovial cell counts. A correlation of relatively low statistical significance with the erythrocytes in joint fluid (r = +0.300; n = 51; P < 0.05) was of a similar order to the equivocal relation found between plasma fibronectin and haemoglobin. Synovial fluid fibronectin levels showed no overall significant correlation with immunoglobulin or acute-phase protein levels, nor with the activity of two enzymes (5'-nucleotidase and acid phosphatase) in the fluid. Nor was there a relationship to most systemic indices of disease activity or drug therapy. But comparing the patients with the seven highest fibronectin levels in joint fluid with a similar number of patients with the lowest levels, in relation to mean values, there appeared to be an inverse relation between levels of synovial fluid fibronectin and of either serum C-reactive protein or haptoglobin (Table  3) . However, this could not be substantiated by formal analysis of the data by Wilcoxon's rank-sum test (P > 0.10).
Fibronectin in synovial smears
Amorphous acellular particles and others which were fibrillar in shape gave positive immunofluorescent staining for fibronectin. When the same smears were stained with phosphotungstic acid/haematoxylin this material gave the characteristic dark blue reaction of fibrin.
Fibronectin was not demonstrable in or on the surface of the cells in these smears by immunofloorescence.
Discussion
In confirmation of a report by Fryand et al. t221 we have found the plasma level of fibronectin in uncomplicated rheumatoid arthritis to be similar to that found in health. However, there is evidence [41 that, unlike most other plasma proteins, fibronectin is synthesized, not in the liver but peripherally by connective tissue cells. It has been suggested [23, 241 that plasma fibronectin originates as the secretory product of fibroblasts, since plasma fibronectin is immunologically closely related to the cell membranerelated protein produced by these cells and released into their environment. If this is correct, it might be expected that plasma levels would only be increased with widespread and severe involvement of connective tissues throughout the In contrast, the raised levels of fibronectin in synovial fluid in rheumatoid arthritis (and, to a lesser extent, in other arthritides), which we now report, may be accounted for by a localized increase in production of this glycoprotein actually at the site of the articular disease. Hence the level of fibronectin in the synovial fluid may possibly serve as an indicator of the stimulation of synovium by disease, unlike indirect tests such as the erythrocyte sedimentation rate, or the levels of acute-phase reactants which are dependent on increased protein synthesis by the liver in response presumably to more generalized stimuli.
Our results establish not only that synovial fluid fibronectin levels are unrelated to overall indices of inflammatory activity in rheumatoid arthritis, but also that no correlation can be shown with synovial fluid polymorphonuclear leucocyte counts or with 5-nucleotidase levels, which reflect inflammation within the joint [25, 261. The weak relationship we have found between fibronectin levels and the erythrocyte count in synovial fluid is not readily explicable and needs further study.
Our previous studies of the immunohistological distribution of fibronectin in the synovium [5] showed that, although it was immunologically distinct from fibrin or fibrinogen, it was often codistributed with fibrin deposited on the surface of synovial villi or on 'rice-bodies' taken from rheumatoid joints. This codistribution was assumed to occur because of adsorption of fibronectin on fibrin, in keeping with the strong avidity which is known to be characteristic of the interaction between these two proteins [271.
M Y .
From examination of the particulate deposits in synovial fluid from some of our patients with rheumatoid arthritis we now find this codistribution in very early fibrin strands and amorphous deposits in the fluid. Our previous work had also shown fibronectin to be present within, and presumably synthesized by, fibroblasts and synovial cells (and in addition to be associated with early immature collagen, but not fully formed fibrous tissue). These latter observations suggest fibronectin may play a transient but possibly important part in the structural organization of tissues concerned with healing and repair in chronically involved joints.
Fibronectin does not serve as a yardstick by which to measure ongoing activity in a joint. But its presence in increased concentrations relative to plasma in synovial fluid may be of significance in relation to the outcome of the arthritic process. Electron-microscopical studies have divided synovial cells into A (macrophage-like) and B (fibroblast-like) cells 1281. It has been suggested that the interaction of fibronectin with nonbacterial particulate material [291 opsonizes the subsequent uptake of such material by phagocytic cells. We have demonstrated fibronectin on fibrin strands and amorphous deposits in synovial fluid. The fate of these deposits is uncertain but the possibility that fibronectin, a product of the fibroblast-like synovial B cells, may act as an opsonizing factor for macrophages derived from synovial A cells is an hypothesis that merits further study. It may explain the role of fibronectin in the acute phase of joint disease as that of facilitation of the removal and disposal of debris and detritus from the joint space.
In conclusion, therefore, it would seem that the local production of fibronectin with arthritic joints may influence either the resolution, or the organization and repair, of intra-articular structures (the former process being most evident in acute disease and the latter in the healing or chronically affected joint). These dual aspects of fibronectin's role in modifying the response characteristic of a potentially chronic and disabling disease like rheumatoid arthritis seem worthy of continued study.
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